FDA expands approval of libido drug Addyi for postmenopausal women
Read Original Source
In this Aug. 18, 2015 file photo, Sprout Pharmaceuticals CEO Cindy Whitehead holds a bottle for the female sex-drive drug Addyi in Raleigh, N.C. (AP Photo/Allen G. Breed, File) The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File) The U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency’s campus in Silver Spring, Md., Aug. 2, 2018.
AI Summary
Main Idea: The FDA has expanded approval of Addyi, a female libido drug from Sprout Pharmaceuticals, so it can now be used by some postmenopausal women up to age 65.
Key Points:
- Addyi was first approved 10 years ago for premenopausal women with low sex drive linked to emotional distress.
- The drug has faced concerns over side effects, including dizziness and nausea, and it carries a warning about mixing it with alcohol.
- Sprout says the new FDA decision is the result of years of work to improve focus on women’s sexual health.
- The condition Addyi treats is still debated, and doctors are told to rule out other causes of low libido before prescribing it.
Impact on the People
Negative Impact
Addyi can cause dizziness, nausea, and dangerous low blood pressure if mixed with alcohol, so some patients may face safety risks and extra caution.
Positive Impact
The FDA expansion gives some postmenopausal women up to age 65 another treatment option for low sex drive and may improve quality of life.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:Sprout Pharmaceuticalscompany
Candidate Entities6 candidates · 5 weighted vote min · 70% decision
- Sprout PharmaceuticalscompanyPrimaryEvaluated
Manufacturer and marketer of Addyi; the article centers on its drug and the FDA update.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Food and Drug Administrationgovernment agency or bodyPrimaryAI selected
Central regulator that expanded approval of Addyi for postmenopausal women up to age 65.
Include 0 (0%)Ignore 0 (0%)5 to threshold - CEO Cindy EckertpersonMajorAI selected
Sprout CEO quoted on the approval and the company’s long effort to change women’s sexual health treatment.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Even the Scorenonprofit / NGOContextCandidate
Advocacy group mentioned for its lobbying campaign supporting approval of the drug.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Hubert Humphrey Building Auditoriumgovernment agency or bodyMentionCandidate
Mentioned only as part of the photo caption and not as an acting entity.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Silver SpringcityMentionCandidate
Location of the FDA campus in a photo caption, not an actor in the story.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment